Here are five takeaways:
1. The company earned $11.5 million in this financing round.
2. The round was led by investors Research Corporation Technologies and California Technology Ventures.
3. The funds will be used to expand sales and distribution and further support the continued rollout of the company’s QB1 system.
4. The CyMedica QB1 system is intended for the treatment of quadriceps muscle atrophy.
5. In April, the system received 510(k) clearance and it was launched at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles.
More articles on devices:
SpineGuard completes $3.1M fresh equity round — 5 things to know
ApiFix used in 50th scoliosis correction — 5 key notes
InVivo Therapeutics names Dr. James Guest to scientific advisory board — 5 key notes
